CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked faithfully but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV happen to be closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past several shares. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set out all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire employment interview that I came away with a bad opinion of the business.

Irony of irony, my bad viewpoint of the company has grown steadily, although the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your therapy as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of this know-how and connected intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) plus the very first brand new drug program endorsement ($5 million), as well as royalty payments of five % of net sales after commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and multiple therapies, it’s this single remedy and a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple disease types, multiple presentations and multiple publications.

Might all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself with the really start of my interest in this business. Judging by the multiples of thousands of diverse comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or maybe some may say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News